SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452
207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

(₹ In million)

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026

Sr.No.	Particulars	Quarter ended 30-09-2026	Quarter ended 30-06-2026	Quarter ended 30-09-2025	Half Year ended 30-09-2026	Half Year ended 30-09-2025	Year ended 31-03-2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
I	Revenue from Operations	2,062.97	1,897.47	1,998.33	3,960.44	3,449.07	8,278.75
II	Other Income	22.92	26.48	27.25	49.40	53.99	114.87
III	**Total Income**	**2,085.89**	**1,923.95**	**2,025.58**	**4,009.84**	**3,503.06**	**8,393.62**
	Expenses						
	a) Cost of Materials Consumed	924.55	1,094.00	606.83	2,018.55	1,044.59	2,651.18
	b) Purchase of Stock in Trade	-	-	-	-	-	-
	c) Change in inventories of finished goods , work in progress & stock in trade.	(213.95)	(530.15)	(49.53)	(744.10)	(169.57)	(110.89)
	d. Employee benefit expenses	261.43	284.90	244.81	546.33	471.69	966.80
	e. Finance Cost	4.57	3.74	4.15	8.31	9.27	18.89
	f. Depreciation & amortisation expense	94.59	89.40	66.39	183.99	130.90	284.09
	g. Other expenditure	636.92	574.14	469.75	1,211.06	858.88	1,831.18
IV	**Total Expenses**	**1,708.11**	**1,516.03**	**1,342.40**	**3,224.14**	**2,345.76**	**5,641.25**
V	Profit/(loss) before Exceptional Items & Tax (III - IV)	377.78	407.92	683.18	785.70	1,157.30	2,752.37
VI	Exceptional Items	-	-	-	-	-	(4.58)
VII	**Profit/(loss) before Tax (V-VI)**	**377.78**	**407.92**	**683.18**	**785.70**	**1,157.30**	**2,747.79**
VIII	**Tax Expense**						
	a) Current Tax	63.87	85.13	151.58	149.00	256.93	614.33
	b) Deferred Tax	21.41	82.36	27.33	103.77	48.20	42.26
IX	**Profit/(Loss) for the period from Continuing Operations (VII-VII)**	**292.50**	**240.43**	**504.27**	**532.93**	**852.17**	**2,091.20**
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-	-
XIII	**Profit/(Loss) for the period (IX+XII)**	**292.50**	**240.43**	**504.27**	**532.93**	**852.17**	**2,091.20**
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	(13.70)	8.65	0.45	(5.05)	(2.42)	(1.33)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	3.45	(2.18)	(0.11)	1.27	0.61	0.34
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (Loss)	(10.25)	6.47	0.34	(3.78)	(1.81)	(0.99)
XV	**Total Comprehensive Income for the period (XIII+XIV)**	**282.25**	**246.90**	**504.61**	**529.15**	**850.36**	**2,090.21**
XVI	Paid-up Equity Share Capital (face value ₹ 2/- each)	160.97	160.97	160.97	160.97	160.97	160.97
XVII	Other Equity						11,816.36
XVIII	Earnings per equity Share						
	(1) Basic (In ₹)	3.63	2.99	6.27	6.62	10.59	25.98
	(2) Diluted (In ₹)	3.63	2.99	6.27	6.62	10.59	25.98



Supriya Lifescience Limited

Standalone Balance Sheet as at September 30, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	September 30, 2026	March 31, 2026
ASSETS		
Non-current assets		
(a) Property, plant and equipment	7,286.08	6,833.17
(b) Right to Use Asset	48.20	45.23
(c) Capital Work in progress	71.27	355.48
(d) Intangible Assets	11.79	13.12
(e) Financial Assets		
(i) Investments	1,066.39	985.23
(ii) Loans and Advances	-	-
(f) Other Non- Current Assets	27.92	15.81
Total Non-current assets	**8,511.65**	**8,248.04**
Current assets		
(a) Inventories	2,651.68	1,595.97
(b) Financial Assets		
(i) Loans and Advances	5.07	5.69
(ii) Trade receivables	1,255.80	2,194.48
(iii) Cash and cash equivalents	410.21	274.80
(iv) Bank balances other than (iii) above	349.10	100.65
(v) Other Financial Assets	-	-
(c) Other current assets	1,033.30	1,151.44
Total Current Assets	**5,705.16**	**5,323.03**
TOTAL ASSETS	**14,216.81**	**13,571.07**
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity share capital	160.97	160.97
(b) Other equity	12,265.03	11,816.36
Total Equity	**12,426.00**	**11,977.33**
LIABILITIES		
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Lease Liabilities	54.85	51.89
(iii) Other financial liabilities	-	-
(b) Provisions	15.45	18.97
(c) Deferred tax Liabilities	416.20	312.44
Total Non-Current Liabilities	**486.50**	**383.30**
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	-	-
(ii) Lease liabilities	3.18	2.46
(iii) Trade payables		
- Micro Enterprises and Small Enterprises	429.31	170.01
- Other than Micro Enterprises and Small Enterprises	641.78	938.46
(iii) Other financial liabilities	106.89	20.40
(b) Provisions	9.38	16.71
(c) Other current liabilities	113.77	62.40
Total Current Liabilities	**1,304.31**	**1,210.44**
TOTAL EQUITY AND LIABILITIES	**14,216.81**	**13,571.07**

SUPRIYA LIFESCIENCE LTD. MUMBAI

Supriya Lifescience Limited

Cash flow statement for the period ended September 30, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	September 30, 2026	March 31, 2026
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	**785.70**	**2,747.79**
Adjustments for		
Depreciation and Amortization	183.99	284.09
Interest Income (Net of Expenses)	(38.87)	(94.54)
Dividend Received	-	(0.00)
Employee Benefit	(15.90)	9.24
Loss on Sale of fixed Assets	-	0.09
Modification of Lease	-	-
Operating profit before working capital changes	**914.92**	**2,946.67**
Adjustments for movement in working capital		
Adjustments for (increase)/ decrease in operating assets		
Trade Receivables	938.69	(850.85)
Inventories	(1,055.71)	(412.48)
Other Non Current & Current Assets	(142.42)	(39.72)
Other Non Current & Current Financial Assets	-	7.11
Loans and Advances	0.62	3.58
	(258.82)	**(1,292.36)**
Adjustments for increase/ (decrease) in operating liabilities		
Trade payables	(37.38)	363.01
Other Non Current & Current Financial Liabilities	86.49	2.80
Other Non Current & Current liabilities	51.36	(31.34)
	100.47	**334.47**
(Income tax paid)/net of refund	(147.73)	(613.99)
Net Cash generated from Operating Activities (A)	**608.84**	**1,374.79**
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(354.34)	(1,522.35)
(Purchase)/ Sale of Investments	(81.16)	(352.82)
Interest Income	47.18	113.43
Dividend Received	-	0.00
Net Cash generated/(outflow) from Investing Activities (B)	**(388.32)**	**(1,761.74)**
C CASH FLOW FROM FINANCING ACTIVITIES		
Increase/(Decrease) in Long term borrowings	-	-
Increase/(Decrease) in Short term borrowing	-	-
Finance Cost	(8.31)	(18.89)
Dividend Paid	(80.48)	(80.48)
Repayment of Lease liability	3.68	0.55
Net Cash generated from Financing Activities (C)	**(85.11)**	**(98.82)**
Net Increase/(Decrease) in Cash and Cash equivalents (A+B+C)	135.41	(485.77)
Cash and Cash Equivalents at the end of previous period	274.80	760.57
Cash and Cash Equivalents as at the end of the reporting period	**410.21**	**274.80**

SUPRIYA LIFESCIENCE LTD. MUMBAI

Notes:-

1. The above standalone unaudited financial results of the Company for the half year ended and quarter ended September 30, 2026 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.

2. The above standalone unaudited financial results of the Company for the half year ended and quarter ended September 30, 2026 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on November 06, 2026.

3. The material intended for export in Quarter 1 of FY 2026-27 was detained by Customs during transit. After obtaining clearance and release from Customs, the material was successfully exported on October 02, 2026.

4. The company does not have any subsidiary/associate/joint venture company as on September 30, 2026.

5. The figures of the previous periods have been regrouped wherever necessary to confirm to the current period presentation.

For Supriya Lifescience Limited

SUPRIYA LIFESCIENCE LTD. MUMBAI

Dr. Saloni Wagh
Managing Director
DIN: 08491410

Place :- Mumbai
Date :- November 06, 2026